Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 8Brain Neoplasms 5Neoplasms 4Glioma 3Medulloblastoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Ketosis 1Insulin Resistance 1Gliosarcoma 1Diabetes Mellitus 1Colonic Neoplasms 1Cognitive Dysfunction 1Chondrosarcoma 1Cholangiocarcinoma 1Astrocytoma 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 22Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8Drug Therapy 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × Metformin × CNS × Clear all
NCT01430351 2025-05-07

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

M.D. Anderson Cancer Center

Phase 1 Terminated
144 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡